Posted by ABMN Staff on Apr 19th, 2024
Investment analysts at StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the specialty pharmaceutical company’s...
More of this article »